AAWH · Ascend Wellness Holdings, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $29.1M | Q2 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 22.8% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Gross Margin non-GAAP | 46.2% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | $19.5M | Q2 2026 | — |
| Net Debt non-GAAP | $251.8M | Q2 2026 | — |
| retail footprint | 55 | Q2 2026 | — |
| Adjusted Gross Profit non-GAAP | $53.93M | Three Months Ended March 31, 2026 | — |
| Retail dispensaries | 51 | as of May 13, 2026 | — |
| retail stores | 47 | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AAWH
this stock
Ascend Wellness Holdings, Inc.
|
$80.51M | -45.5% | -10.9% | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.59B | +15.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.41B | +2.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.15B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- HighPoint Advisor Group L…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AAWH | -17.7% | +2.6% | -29.1% | +2.6% | -45.5% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -18.2% | -0.4% | -42.5% | -0.4% | -58.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.